Citi lowered the firm’s price target on Revvity to $125 from $160 and keeps a Buy rating on the shares post the Q3 report. The drivers of the reduced fiscal 2023 guidance included biopharma customer headwinds and pressure across reagents, software, instruments, and applied genomics, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RVTY: